Adaptimmune Therapeutics PLC (ADAP) is experiencing significant momentum in its stock performance. After a remarkable 52% surge on Wednesday, the penny stock is up again by almost 11% in pre-market trading on Thursday, October 9. This surge comes despite a notably low “Sell (E+)” rating from Weiss Ratings. The latest surge in ADAP stock seems driven primarily by speculative momentum rather than fundamentals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
For context, Adaptimmune Therapeutics specializes in T-cell therapies for treating solid tumor cancers. While ADAP rallied sharply, the stock is still down over 60% this year, reflecting investor concerns. Over the past 12 months, the stock has fallen by more than 75%, trading within a 52-week range of $0.04 – $0.91.
ADAP Stock Gets a Sell Rating
On October 8, Weiss Ratings assigned ADAP a “Sell (E+)” rating, which is an unusually low grade indicating deep concerns about the company’s financial health and prospects.
Notably, Weiss Ratings is an independent U.S. financial research firm that grades stocks, ETFs, mutual funds, banks, and insurers. The “Sell (E+)” is one of the lowest possible ratings on its scale, which signals very high risk and poor investment quality.
This downgrade adds to a series of bearish assessments from other Wall Street analysts. For instance, five-star-rated analyst Michael Schmidt at Guggenheim downgraded ADAP stock from Buy to Hold in July. Meanwhile, analyst Peter Lawson at Barclays reiterated his Sell rating on ADAP in August.
ADAP Gets a Neutral Rating from AI Analyst
According to TipRanks’ A.I. Stock Analysis, ADAP stock has earned a Neutral rating with a score of 44 out of 100. Adaptimmune’s overall score is weighed down by weak financial performance, including declining revenues, persistent losses, and a fragile balance sheet. While technical indicators suggest a mildly positive short-term trend, overall metrics continue to reflect deep financial challenges.
The tool also highlights both the positive and negative factors influencing the stock’s performance. A screenshot of the analysis is shown below.
What’s Next for Investors?
For Adaptimmune investors, the road ahead looks uncertain. Despite this week’s sharp rebound, the stock remains deeply in the red for 2025 and continues to face fundamental challenges, including limited revenue visibility. With Weiss Ratings issuing a rare “Sell (E+)” grade and no major catalysts on the horizon, sentiment is likely to remain cautious.
Looking ahead, investors should monitor liquidity trends, upcoming trial updates, and any strategic developments that could improve confidence in the company’s long-term outlook.
Is Adaptimmune Therapeutics a Buy?
Turning to Wall Street, ADAP stock carries a Hold consensus rating, based on three Holds and one Sell assigned over the last three months. Moreover, the average Adaptimmune stock price target of $0.28 implies a 33% upside potential from current levels.
